Xyosted (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04601233 (ClinicalTrials.gov) | January 4, 2021 | 2/10/2020 | Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis | Testosterone TReatment for Erectile Dysfunction in Male Multiple Sclerosis Patients With Low Testosterone (TTRED-MS Study) | Multiple Sclerosis;Erectile Dysfunction;Testosterone Deficiency | Drug: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector | Tulane University | Louisiana State University Health Sciences Center in New Orleans;Antares Pharma Inc. | Not yet recruiting | 18 Years | N/A | Male | 20 | Phase 4 | United States |